Curis, Inc. (NASDAQ:CRIS) Q2 2023 Earnings Call Transcript

So in each of these groups of N equals 3, we’ve got two of three so far, we need two or three more in the next 17 patients, in each of those groups. And if we can get that and we can make a pretty compelling case that this novel therapeutic does seem to offer a compelling benefit worth discussion.

Unidentified Analyst: Got it. Understood. Thank you so much, and congrats again.

Jim Dentzer: Thank you very much. I appreciate it. Thank you for your support.

Operator: This concludes our question-and-answer session. I would like to turn the conference back over to the company’s President and Chief Executive Officer, Mr. James Dentzer for any closing remarks. Please go ahead, sir.

Jim Dentzer: Thank you, operator, and thank you everyone for joining today’s call. As always, thank you to the patients and families participating in our clinical trials to our team at Curis for their hard work and commitment, and to our partners at Aurigene, ImmuNext and the NCI for their ongoing collaboration and support. We look forward to updating you again soon. Operator?

Operator: The conference is now concluded. Thank you again for your participation. You may now disconnect.